ResMed (RMD) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
ResMed (RMD) share price 'may have overcompensated' - Morgan Stanley
October 27, 2023 11:38 AM EDTMorgan Stanley upgraded shares of ResMed (NYSE: RMD) to Overweight from Equal-Weight, lowering the price target on the stock to $169 from $180 per share in a note to clients Friday.
Analyst Sean Laaman told investors that their deep dive analysis on the obstructive sleep apnea (OSA) market suggests the... More



